Home
Oncology
Oncology Pipeline
LipoADC™ Platform – K1
TRAFsome™ T cell Engager – HF50
Immune Modulator – K16
Gene Therapy
Gene Therapy Pipeline
HFG1
Facilities
About
News & Publications
Contact
简体中文
Home
Oncology
Oncology Pipeline
LipoADC™ Platform – K1
TRAFsome™ T cell Engager – HF50
Immune Modulator – K16
Gene Therapy
Gene Therapy Pipeline
HFG1
Facilities
About
News & Publications
Contact
简体中文
September 18, 2024
BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
Click here
by
PJWCreative
0
0
English
English
简体中文
English
English
简体中文